Research Information System
Thesis Type: Expertise In Medicine
Institution Of The Thesis: Gazi Üniversitesi, Tıp Fakültesi, Turkey
Approval Date: 2019
Thesis Language: Turkish
Student: PINAR ÇAKMAK
Supervisor: İPEK IŞIK GÖNÜL
Open Archive Collection: AVESIS Open Access Collection
Abstract:Classification of glioblastoma, which is the most frequent and highly aggressive, primary brain neoplasm in adults, has been based on genetic alterations, especially IDH mutation. p53 mutation is related to the progression of a lower grade glioma and frequently seen with IDH mutant glioblastomas. The current therapy strategy for glioblastomas is, after a maximum surgical resection, conventional radiotherapy combined with temozolamide. Studies about targeting the cellular pathways altered in glioblastoma are getting more important. In our study, 349 glioblastoma cases’ clinical and histological properties were reexamined, who was diagnosed at Gazi University Hospital, Pathology department, between years 2008-2017. Each case was immunohistochemically stained with IDH1, p53, RPS6, and pAKT antibodies. According to analysis, median overall survival is 12,42 months, cumulative survival rates for glioblastoma patients are: For 1 year 50,4%; for 2 years 22,0%; for 3 years 13,9% and for 5 years 1%. The most important result is we haven’t found a relation with IDH expression and overall survival, however, 116 being more than 55 years old at diagnosis and having a tumor includes intense VEP, cause a 1,5 fold higher risk for exitus. IDH1 positive and p53 expression high groups have younger patient age; younger age of diagnosis. Previous brain tumor history is higher in these two groups. Also, IDH1 negative group has a higher expression rate for the RPS6 antibody. These findings are compatible with the literature